Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Phase 4
94
about 1.3 years
18+
1 site in GA
About this study
This trial is testing whether a premedication regimen with methylprednisolone or dexamethasone helps prevent allergic reactions to motixafortide in patients with multiple myeloma undergoing stem cell mobilization. The goal is to determine which medication, methylprednisolone or dexamethasone, is better at preventing these reactions.
Based on ClinicalTrials.gov records.
What participants do
- 1.Electronic Health Record Review
- 2.Questionnaire Administration
- 3.Receive Recombinant Granulocyte Colony-Stimulating Factor
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
paracetamol (Reduces fever and pain (mechanism not fully understood)), dexamethasone, famotidine, loratadine, methylprednisolone, montelukast (Leukotriene receptor antagonist; reduces inflammation in airways), motixafortide, colony stimulating factor
oral, injection, ocular, oral (Oral Tablet), oral (Disintegrating Oral Tablet), injection (Injection), subcutaneous
Secondary: Compare Tolerability Between Regimens, Cytokine levels
diagnostic
Oncology